Induction of Collagen I by CXCL10 in Ovarian Theca–Stroma Cells via the JNK Pathway

Chaojun Wang1,2 and Yun Sun1,2*

1 Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China,
2 Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China

Premature ovarian insufficiency (POI) poses a great threat to reproductive-age women. Ovarian fibrogenesis is a basic histologic feature of POI. Ovarian theca–stroma cells are responsible for ovarian fibrosis, but few studies have focused on the ovarian microenvironment. The role and mechanism of chemokines in the development of POI remain unclear. Here, we evaluated C-X-C motif chemokine ligand 10 (CXCL10) in biochemical POI patients, POI patients, and a POI mouse model. CXCL10 levels in serum and follicular fluid were higher in both bPOI and POI patients than in controls. An increased level of CXCL10 was also observed in a POI mouse model. CXCL10 concentrations in serum and follicular fluid were positively associated with follicle-stimulating hormone and negatively associated with antral follicle count. Our study for the first time found that CXCL10 induced COL1A1 and COL1A2 production, two subunits of collagen I in mouse theca–stroma cells by activating the JNK/c-Jun pathway. Inhibition of JNK and c-Jun attenuated the increases of COL1A1 and COL1A2 caused by CXCL10. Moreover, CXCL10 had no effects on hormone synthesis, proliferation, and apoptosis in human luteinized granulosa (hGL) cells. Our findings revealed a potential diagnostic value of CXCL10 in the early stage of POI and shed new insights into the biological function of CXCL10 in ovarian fibrosis.

Keywords: premature ovarian insufficiency, CXCL10, collagen, luteinized granulosa cells, ovarian theca–stroma cells

INTRODUCTION

The prevalence of infertility ranges from 8% to 12% (1). Premature ovarian insufficiency (POI) is a common cause of infertility among reproductive-age women. POI refers to the cessation of ovarian function in women under the age of 40 years. The core features of POI include high follicle-stimulating hormone (FSH) and increased risks of degenerative health problems, including cognitive impairment, cardiovascular disease, and osteoporosis (2). Three stages of the disorder have been demonstrated, namely, occult or subfertility, biochemical POI (bPOI) with a high level of FSH, and overt POI with irregular menstruation (3). It is worth noting that an effective strategy to rescue ovarian function rarely exists in overt POI patients. Therefore, a biomarker that could predict the earlier stage of disease is of great importance.
Ovarian theca–stroma cells differentiate into inner theca cells (TCs) and outer myofibroblast (MFB). By secreting large amounts of extracellular matrix (ECM), MFB is involved in tissue fibrosis (4). Collagen I is the most plentiful component of ECM and widely expressed in the ovary (5, 6). A key characteristic of POI is follicle depletion, which is associated with invasion of the ovarian cortex by ovarian stroma or fibrous tissue (7). Immune abnormalities and inflammation can trigger ovarian fibrosis (7, 8). The role of ovarian theca–stroma cells has mainly been reported in polycystic ovary syndrome (PCOS); however, its role in POI is poorly understood (9, 10).

Accumulating evidence indicates that immune dysregulation is one of the contributing factors of POI (11–13). Circulating autoantibodies and oophoritis have been demonstrated to be present in a subset of POI patients (14, 15). A recent study showed that IFN-γ and TNF-α induced apoptosis and suppressed proliferation by activating NF-kB and JAK/STAT1 signaling in a human granulosa-like tumor cell line and mouse primary granulosa cells. In addition, these two cytokines inhibited estrogen production through CYP19A1 (16). However, whether chemokines are involved in ovarian disturbance remains mostly obscure.

Chemokine (C-X-C motif) ligand 10 (CXCL10), also known as interferon-γ-inducible protein (IP-10), is secreted by numerous cell types including endothelial cells, fibroblasts, and macrophages (17, 18). CXCL10 could directly regulate the biology of resident cells by binding to its receptor CXCR3. However, how chemokines are involved in ovarian disturbance remains poorly defined.

In this study, we comprehensively elucidated for the first time the effects of CXCL10 on disruption of ovarian function in samples from POI patients and in an experimental POI mouse model.

MATERIALS AND METHODS

Recruitment of Patients

A total of 64 women with diverse ovarian reserves, consisting of 23 patients with bPOI, 19 patients with POI, and 22 control women, were enrolled from the Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University from May 2019 to June 2020. The research was approved by the Ethics Committee of Renji Hospital with written informed consent from all participants. Women under 40 years of age with an FSH level higher than 25 IU/L on two occasions more than 4 weeks apart are diagnosed as POI. The diagnosis of bPOI was based on FSH level ≥10 IU/L but <25 IU/L and anti-Müllerian hormone (AMH) <1.1 ng/ml. The control group included women who had undergone the first cycle of IVF or ICSI (11–13). Circulating autoantibodies and oophoritis have been demonstrated to be present in a subset of POI patients (14, 15). A recent study showed that IFN-γ and TNF-α induced apoptosis and suppressed proliferation by activating NF-kB and JAK/STAT1 signaling in a human granulosa-like tumor cell line and mouse primary granulosa cells. In addition, these two cytokines inhibited estrogen production through CYP19A1 (16). However, how chemokines are involved in ovarian disturbance remains poorly defined.

In this study, we comprehensively elucidated for the first time the effects of CXCL10 on disruption of ovarian function in samples from POI patients and in an experimental POI mouse model.

Sample Collection and Laboratory Tests

Venous blood was obtained from 23 patients with bPOI, 19 patients with POI, and 22 control women on day 3 of the menstrual cycle before their first cycle of IVF or ICSI treatment. The levels of hormones including FSH, luteinizing hormone (LH), progesterone (P₄), estradiol (E₂), and AMH were detected by electrochemiluminescence immunoassay kits (Roche, Germany).

The antral follicle count (AFC) of 64 women with diverse ovarian reserves in the early follicular phase was tested through transvaginal ultrasonography.

Follicular fluid was collected from 23 bPOI patients and 22 control women. After ovarian stimulation, women with bPOI and controls underwent oocyte retrieval guided by transvaginal B-scan ultrasound. Ovarian stimulation and oocyte retrieval were based on the conventional protocols of the Center for Reproductive Medicine, Renji Hospital. Follicular fluid from the first large follicle (diameter ≥ 14 mm verified by ultrasound) was collected after the removal of the cumulus complex. Clear follicular fluid without blood contamination was included and centrifuged at 2,500 rpm for 10 min. All samples were stored at −80°C until used. Follicular fluid from the other large follicles of control women undergoing IVF or ICSI was used for primary luteinized granulosa cell isolation.

Establishment of a POI Mouse Model

All the animals and procedures were approved and supervised by the Institutional Animal Care and Use Committee at Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Female Balb/c mice aged 6–8 weeks (Jiesijie Laboratory Animal, China) were housed under 20°C–25°C temperature and 40%–70% humidity and fed a standard diet. Mice were used in the experiment after acclimatization for 1 week. Mice were divided into the control group (n = 10) and experimental group (n = 10) randomly. Zona pellucida glycoprotein 3 peptide (ZP3) was purchased from GL Biochem (Shanghai, China) with 95% purity. ZP3 was dissolved and sterilized at 1 mM in double-distilled water, and then emulsified with an equal volume of complete immune adjuvant (CFA, Mycobacterium tuberculosis H37RA strain, Sigma, USA). The mice were injected with 0.1 ml of emulsion subcutaneously into the hind footpad after anesthetization with isoflurane. The same method was repeated twice with ZP3 emulsified in incomplete immune adjuvant (IFA, Sigma, USA). The POI mouse model was established 2 weeks later. The mice of the control group were injected with the same volume of saline into the same sites. The four different periods of the estrus cycle (proestrus, estrus, metestrus, and diestrus) were detected via vaginal smears. In brief, vaginal secretions were collected at 8 a.m. every day with fine tip pipettes, then stained with methylene blue and observed by microscopy.

Hematoxylin and Eosin Staining and Follicle Counting

Mice were euthanized at the end of the study and ovaries were collected, which were fixed and used for histopathology examination by hematoxylin and eosin (H&E) staining. Ovary...
tissues were then sectioned at 5 μm. The follicles with an oocyte containing a clearly visible nucleus were counted. Meanwhile, follicles were divided into primordial, primary, secondary, and atretic ones, as previously described (19, 20). We selected five slides randomly for each group and chose five views on each slide for statistical analysis in a blinded manner.

**Isolation and Culture of Primary Human Luteinized Granulosa Cells**

Human luteinized granulosa (hGL) cells were isolated from follicular fluid of control women undergoing IVF or ICSI with tubal or male factor-related infertility as previously described (21). Briefly, cells were obtained by Ficoll-Paque (GE Healthcare, Sweden) after isolation of oocytes and digested with hyaluronidase for 7 min at 37°C. After digestion termination, cells were collected by centrifugation (1,000 rpm, 5 min) and cultured in DMEM/F12 with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin sulfate.

**Isolation and Culture of Ovarian Theca–Stroma Cells**

Ovarian theca–stroma cells were obtained from 3- to 4-week-old Balb/c immature mice. In brief, ovaries were isolated from the bursa and poked with insulin needles. After about 100 times, the granulosa cells and oocytes were released. The tissue mixture was digested with pre-equilibrated enzymatic media containing 0.7 mg/ml Collagenase IV (Thermo Fisher Scientific, USA) and 0.2 mg/ml DNase I (Thermo Fisher Scientific, USA) at 37°C for 1 h. The enzymatic digestion was neutralized with an equal volume of serum and 100 U/ml penicillin. After overnight incubation, the undigested tissue. Cells were centrifuged (1,000 rpm, 5 min) and suspended in McCoy’s 5A medium with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin sulfate.

**Masson Staining**

Collagen fibers were detected by Masson trichrome staining of ovary tissues from POI mice and control mice. The ovaries of each mouse were harvested and fixed with 4% paraformaldehyde for 24 h. After the paraffin embedding and sectioning process (5 μm in thickness), the ovaries were stained with Masson trichrome. The slides were photographed and analyzed under a light microscope. Collagen fibers were stained blue, muscle fibers and cytoplasm were stained red, and the nuclei were stained black.

**Extraction of RNA for qRT-PCR**

Total RNA from cells was isolated using an RNA extraction kit (Foregene, China) and was reverse-transcribed to cDNA with a PrimeScript RT Master Mix Perfect Real-Time kit (Takara, Japan). The target mRNA was quantified with qRT-PCR. The relative mRNA values were normalized to the GAPDH gene control values and calculated using the comparative cycle threshold (ΔΔCt) method.

The primer sequences were as follows: COL1A1 forward 5′-GCTCTCTTAGGGGCGACT-3′, reverse 5′-CCACGTCTCACCATTGGGG-3′; COL1A2 forward 5′-AAGGGTGCTACTGGACTCCC-3′, reverse 5′-TTGTTACCGGATTCTCTTTTG-3′; and GAPDH forward 5′-AGGCCGGGTGCTGATGTATGC-3′, reverse 5′-TGCCCTGCTCACCTTCT-3′.

**Protein Extraction for Western Blotting**

The cells were homogenized in an ice-cold radioimmunoprecipitation assay lysis buffer (CBioBio, China) containing a phosphatase inhibitor (Active Motif, USA) and a protease inhibitor (Roche, Switzerland). After quantification of protein concentration by a BCA kit, 40 μg of each sample was separated by 10% or 15% SDS-PAGE gels according to molecular weight, and then transferred onto PVDF membranes. After blocking with 5% BSA for 1 h at room temperature, the blot was incubated with different antibodies against PCNA (1:2,000, Proteintech, China), Bax (1:5,000, Proteintech, China), Bcl2 (1:2,000, Proteintech, China), COL1A1 (1:500, Servicebio, China), COL1A2 (1:2,000, Proteintech, China), JNK (1:3,000, Proteintech, China), phospho-JNK (1:1,000, Proteintech, China), c-Jun (1:1,000, Cell Signaling Technology, USA), phospho-c-Jun (1:1,000, Cell Signaling Technology, USA), tubulin (1:20,000, Proteintech, China), and GAPDH (1:20,000, Proteintech, China). The bands were visualized and captured using a G-Box iChemil Chemiluminescence Image Capture System (Syngene).

**siRNA Transfection**

RNAi-negative controls and specific small-interfering RNAs (siRNAs) against c-Jun were purchased from GenePharma.
A Higher Level of CXCL10 in Serum and Follicular Fluid of bPOI Patients

In our study, 23 women with bPOI, 19 women with POI, and 22 controls were recruited. The clinical features are shown in Table 1. No differences were observed in terms of age, body mass index (BMI), and basal levels of estradiol and progesterone. Compared with control women, both bPOI and POI patients had a higher level of basal FSH and a lower level of AMH (P < 0.001). As expected, basal antral follicle counts were decreased in patients with bPOI and patients with POI. A higher level of LH was detected in the POI group than in the bPOI and control groups (P < 0.001).

The concentrations of CXCL10 in serum and follicular fluid from bPOI patients were significantly increased than those from control women (P < 0.05, Figures 1A, 2A). In addition, the level of CXCL10 in serum was higher in POI patients than in control women (P < 0.01, Figure 1A). As shown in Figures 1B-D, CXCL10 plasma levels were positively correlated with FSH, but negatively correlated with AMH and AFC (P = 0.003, P = 0.005, and P = 0.022, respectively).

The correlation of CXCL10 levels in follicular fluid and indicators of the ovarian reserve was analyzed in control women and bPOI patients. The level of CXCL10 in follicular fluid was positively associated with serum FSH (P = 0.019, Figure 2B) and negatively with AFC (P = 0.003, Figure 2D), but was unrelated to serum AMH level (P = 0.072, Figure 2C).

Abundance of CXCL10 in POI Mice

To further verify the role of CXCL10 in POI, a ZP3-induced POI mouse model was established. Irregular estrous cycles, elevated plasma FSH level, and declined estradiol level were observed in the POI group compared with the control group (P < 0.01, Figures 3A–C). Ovarian morphological examination showed that functional follicles, including primordial, primary, and secondary follicles, were significantly reduced in POI mice (P < 0.01, P < 0.01, and P < 0.05, respectively, Figures 3D, E). There was no difference in the number of atretic follicles between POI mice and the control group (P > 0.05, Figure 3E). Compared with control mice, the serum level of CXCL10 was significantly higher in the POI group (P < 0.01, Figure 3F).

CXCL10 Had no Effect on Human Luteinized Granulosa Cells

Both ovarian granulosa cells and theca-stroma cells are indispensable for normal ovarian function. To assess the effects of CXCL10 on ovarian hGL cells, we examined hormone synthesis, cell proliferation, and apoptosis in CXCL10-treated hGL cells. The isolated hGL cells were cultured with different concentrations of CXCL10 for 24 h. As shown in Figures 4A, B, CXCL10 had no effect on the production of estradiol and progesterone (P > 0.05). Western blot revealed that there were no significant differences in the expression of PCNA, Bcl2, and Bax (P > 0.05, Figures 4D, E). The CCK-8 assay showed that CXCL10 did not affect cell viability (P > 0.05, Figure 4C). CXCL10 binds the G protein cognate receptor CXCR3 to exert biological activity. Immunofluorescence staining confirmed the presence of CXCR3 in hGL cells (Figure 4F).

### RESULTS

### A Higher Level of CXCL10 in Serum and Follicular Fluid of bPOI Patients

In our study, 23 women with bPOI, 19 women with POI, and 22 controls were recruited. The clinical features are shown in Table 1. No differences were observed in terms of age, body mass index (BMI), and basal levels of estradiol and progesterone. Compared with control women, both bPOI and POI patients had a higher level of basal FSH and a lower level of AMH (P < 0.001). As expected, basal antral follicle counts were decreased in patients with bPOI and patients with POI. A higher level of LH was detected in the POI group than in the bPOI and control groups (P < 0.001).

The concentrations of CXCL10 in serum and follicular fluid from bPOI patients were significantly increased than those from control women (P < 0.05, Figures 1A, 2A). In addition, the level of CXCL10 in serum was higher in POI patients than in control women (P < 0.01, Figure 1A). As shown in Figures 1B–D, CXCL10 plasma levels were positively correlated with FSH, but negatively correlated with AMH and AFC (P = 0.003, P = 0.005, and P = 0.022, respectively).

The correlation of CXCL10 levels in follicular fluid and indicators of the ovarian reserve was analyzed in control women and bPOI patients. The level of CXCL10 in follicular fluid was positively associated with serum FSH (P = 0.019, Figure 2B) and negatively with AFC (P = 0.003, Figure 2D), but was unrelated to serum AMH level (P = 0.072, Figure 2C).

### Abundance of CXCL10 in POI Mice

To further verify the role of CXCL10 in POI, a ZP3-induced POI mouse model was established. Irregular estrous cycles, elevated plasma FSH level, and declined estradiol level were observed in the POI group compared with the control group (P < 0.01, Figures 3A–C). Ovarian morphological examination showed that functional follicles, including primordial, primary, and secondary follicles, were significantly reduced in POI mice (P < 0.01, P < 0.01, and P < 0.05, respectively, Figures 3D, E). There was no difference in the number of atretic follicles between POI mice and the control group (P > 0.05, Figure 3E). Compared with control mice, the serum level of CXCL10 was significantly higher in the POI group (P < 0.01, Figure 3F).

### CXCL10 Had no Effect on Human Luteinized Granulosa Cells

Both ovarian granulosa cells and theca-stroma cells are indispensable for normal ovarian function. To assess the effects of CXCL10 on ovarian hGL cells, we examined hormone synthesis, cell proliferation, and apoptosis in CXCL10-treated hGL cells. The isolated hGL cells were cultured with different concentrations of CXCL10 for 24 h. As shown in Figures 4A, B, CXCL10 had no effect on the production of estradiol and progesterone (P > 0.05). Western blot revealed that there were no significant differences in the expression of PCNA, Bcl2, and Bax (P > 0.05, Figures 4D, E). The CCK-8 assay showed that CXCL10 did not affect cell viability (P > 0.05, Figure 4C). CXCL10 binds the G protein cognate receptor CXCR3 to exert biological activity. Immunofluorescence staining confirmed the presence of CXCR3 in hGL cells (Figure 4F).

### TABLE 1 | Demographic features of recruited patients.

| Characteristic | Control (n = 22) | bPOI (n = 23) | POI (n = 19) | P-value |
|---------------|-----------------|--------------|-------------|--------|
| Age (years)   | 31.00 ± 0.53    | 32.22 ± 0.41 | 30.16 ± 0.98 | 0.176  |
| BMI (kg/m²)   | 21.89 ± 0.33    | 22.28 ± 0.53 | 22.42 ± 0.24 | 0.407  |
| AFC           | 14.32 ± 0.62    | 5.65 ± 0.55a | 1.58 ± 0.21ab | <0.001 |
| FSH (IU/L)    | 5.68 ± 0.32     | 13.59 ± 0.83a | 37.74 ± 1.88ab | <0.001 |
| LH (IU/L)     | 4.93 ± 0.37     | 6.06 ± 0.78  | 19.76 ± 3.37ab | <0.001 |
| Estradiol (pg/ml) | 28.88 ± 2.38 | 34.09 ± 4.94 | 25.41 ± 3.72 | 0.396  |
| P4 (ng/ml)    | 0.23 ± 0.03     | 0.26 ± 0.03  | 0.19 ± 0.03  | 0.783  |
| AMH (mg/ml)   | 4.01 ± 0.37     | 0.57 ± 0.06a | 0.08 ± 0.02ab | <0.001 |

Hormone levels were measured in serum on day 3 of the menstrual cycle. AFC was detected as the number of follicles (3–8 mm in diameter) by transvaginal ultrasound scan during the early follicular phase.

bPOI, biochemical premature ovarian insufficiency; POI, premature ovarian insufficiency; AFC, antral follicle count; FSH, follicle-stimulating hormone; LH, luteinizing hormone; P4, progesterone; AMH, anti-Müllerian hormone.

*P < 0.05 vs. control.

**P < 0.05 vs. bPOI.
Upregulation of COL1A1 and COL1A2 by CXCL10 in Ovarian Theca–Stroma Cells

Increased collagen abundance was found in the ovarian stroma of POI mice by Masson staining (Figure 5A). In addition, Western blot was conducted on collected mice ovarian tissues. COL1A1 and COL1A2 protein levels were increased in the ovaries from POI mice compared with the control mice (P < 0.01, Figure 5B). To test whether CXCL10 is involved in collagen synthesis during the process of ovarian fibrosis, we incubated primary mouse ovarian theca–stroma cells with different CXCL10 concentrations ranging from 0 to 100 ng/ml for 24 h. The morphology of primary ovarian theca–stroma cells is shown in Figure 6A under a microscope. Vimentin, a marker for theca–stroma cells, and CXCR3 were stained positively (Figure 6B). In-vitro studies demonstrated that CXCL10 upregulated COL1A1 mRNA and protein levels in the concentration of 10 and 100 ng/ml (P < 0.01, Figures 6C, D). Additionally, the levels of mRNA and protein for COL1A2 were increased by CXCL10 in a dose-dependent manner (Figures 6E, F).

Involvement of JNK and c-Jun in the Regulation of Collagen I by CXCL10

JNK signaling is related to inflammation and fibrosis. To evaluate the role of JNK signaling in CXCL10-induced stimulation of collagen I, we examined the phosphorylation of JNK after CXCL10 treatment. Time course studies indicated that JNK phosphorylation was markedly increased by CXCL10 at 15 min in ovarian theca–stroma cells (P < 0.01, Figure 7A). To confirm the involvement of activated JNK in CXCL10-induced collagen synthesis, ovarian theca–stroma cells were treated with CXCL10 in the presence of SP600125 (a JNK inhibitor). SP600125 remarkably inhibited the upregulation of COL1A1 and COL1A2 by CXCL10 (Figures 7B, C). The level of c-Jun phosphorylation peaked at 15 min after treatment with 10 ng/ml CXCL10 in ovarian theca–stroma cells (P < 0.01, Figure 7D). The phosphorylation of c-Jun was inhibited by the JNK inhibitor SP600125 (P < 0.01, Figure 7E). Furthermore, to understand whether c-Jun was required for CXCL10-mediated induction of collagen I, we transfected ovarian theca–stroma cells with c-Jun siRNA. Western blotting showed that the upregulation of COL1A1 and COL1A2 caused by CXCL10 was abolished by knockdown of c-Jun (P < 0.01, Figures 7F, G).

DISCUSSION

In this study, we found that serum CXCL10 levels were increased in women with bPOI and overt POI compared with women with...
normal ovarian function. Furthermore, a negative correlation between AFC and CXCL10 and a positive correlation between FSH and CXCL10 levels in serum and follicular fluid were found in our study. Our findings demonstrated a potential diagnostic value of a high level of CXCL10 in bPOI and POI patients, suggesting that CXCL10 might be associated with the pathogenesis of POI.

The etiologies of POI include iatrogenic factors, genetic aberrations, and metabolic diseases (22). Nevertheless, the majority of POI cases are idiopathic and their causes remain obscure. Currently, there has been much interest in the potential role of chronic inflammation in POI (23). CXCL10 has been found to be elevated in bPOI patients by a recent study (24), which is in line with our result. However, the role and mechanism of CXCL10 in the pathogenesis of POI have never been reported. We for the first time found that CXCL10 led to collagen synthesis in ovarian theca–stroma cells through the JNK pathway. These findings provide preliminary evidence that CXCL10 played an important role in the pathogenesis of POI.

The development and quality of oocytes depend on a complex ovarian stromal milieu (6). Collagen I was the most widely expressed ECM element within ovaries (25). Therefore, it is critical to evaluate the effect of CXCL10 on collagen I expression in ovarian theca–stroma cells for better understanding the loss of ovarian function. As a major member of the ECM family, we discovered that both COL1A1 and COL1A2 mRNA and protein levels were increased by CXCL10, suggesting that CXCL10 might be associated with the development of POI by promoting collagen synthesis and eventually causing ovarian fibrosis.

It is recognized that CXCL10 has quite opposite effects on tissue fibrosis in different organs. CXCL10-deficient mice exhibited less CCI4-induced liver fibrosis than wild-type mice and a neutralizing anti-CXCL10 antibody significantly inhibited hepatic fibrosis (26). Similarly, Berres et al. (27) found a close link of serum CXCL10 with the progression of liver fibrosis after liver transplantation. In contrast, CXCL10 has an antifibrotic effect on lung and kidney fibrosis. Administration of recombinant CXCL10 in a bleomycin model of pulmonary fibrosis reversed the fibrotic phenotype by binding to syndecan-4 (28). Consistent with the results of in-vivo studies, serum CXCL10 level was markedly higher in patients with idiopathic pulmonary fibrosis than in control subjects (29). Zhang and colleagues claimed that recombinant murine CXCL10 attenuated high glucose and TGF-β-induced collagen synthesis in kidney fibroblasts, and this effect was abrogated by the silencing of CXCR3 (30). However, whether CXCL10 activation plays a beneficial or a pathogenetic role in ovarian function. As a major member of the ECM family, we discovered that both COL1A1 and COL1A2 mRNA and protein levels were increased by CXCL10, suggesting that CXCL10 might be associated with the development of POI by promoting collagen synthesis and eventually causing ovarian fibrosis.

It is recognized that CXCL10 has quite opposite effects on tissue fibrosis in different organs. CXCL10-deficient mice exhibited less CCI4-induced liver fibrosis than wild-type mice and a neutralizing anti-CXCL10 antibody significantly inhibited hepatic fibrosis (26). Similarly, Berres et al. (27) found a close link of serum CXCL10 with the progression of liver fibrosis after liver transplantation. In contrast, CXCL10 has an antifibrotic effect on lung and kidney fibrosis. Administration of recombinant CXCL10 in a bleomycin model of pulmonary fibrosis reversed the fibrotic phenotype by binding to syndecan-4 (28). Consistent with the results of in-vivo studies, serum CXCL10 level was markedly higher in patients with idiopathic pulmonary fibrosis than in control subjects (29). Zhang and colleagues claimed that recombinant murine CXCL10 attenuated high glucose and TGF-β-induced collagen synthesis in kidney fibroblasts, and this effect was abrogated by the silencing of CXCR3 (30). However, whether CXCL10 activation plays a beneficial or a pathogenetic role in ovarian function. As a major member of the ECM family, we discovered that both COL1A1 and COL1A2 mRNA and protein levels were increased by CXCL10, suggesting that CXCL10 might be associated with the development of POI by promoting collagen synthesis and eventually causing ovarian fibrosis.
In the present study, we observed a profibrotic effect of CXCL10 on ovarian theca–stroma cells for the first time. The dual role of CXCL10 on organ fibrogenesis may depend on a diverse microenvironment and activated downstream molecules or signaling pathway (31).

The JNK pathway is involved in a range of physiological processes. Several stimuli have been reported to activate the JNK pathway, such as cytokines, chemokines, oxidative stress, and profibrotic factors. Upon activation, JNK can phosphorylate c-Jun at the NH2-terminal domain by which JNK induces the transcription of genes related to inflammatory and fibrotic responses (32). In human lung and periodontal ligament fibroblasts, researchers reported that JNK phosphorylated c-Jun and enhanced AP-1 transcriptional activity, thus promoting collagen I transcription at the AP-1 binding site (33, 34). Accordingly, we observed JNK and c-Jun activation by CXCL10 in ovarian theca–stroma cells. Furthermore, the JNK inhibitor and c-Jun silencing both reversed the CXCL10-induced collagen I production. These results indicated that phosphorylation of JNK and c-Jun was essential for the induction of collagen I transcription by CXCL10, and subsequently, targeting the JNK and c-Jun pathway had a therapeutic potential to alleviate ovarian fibrogenesis.

The present study has a few limitations. Firstly, the number of bPOI, POI, and control subjects was relatively small. Secondly, we did not collect follicle fluid from patients with POI. Thirdly, we could not illustrate the source of CXCL10. Whether it originates from peripheral blood or from intrinsic cells of ovaries remains unclear. There are several types of POI mouse...
FIGURE 4 | CXCL10 had no effect on human luteinized granulosa (hGL) cells. (A–E) The hGL cells were treated with vehicle control (0) and CXCL10 (1, 10, and 100 ng/ml) for 24 h, n = 3. (A) Estradiol levels in culture medium. (B) Progesterone levels in culture medium. (C) Cell viability of hGL cells. (D) Representative Western blot of Bcl2, Bax, and PCNA in hGL cells. (E) Quantitative analysis of Bcl2, Bax, and PCNA protein levels. (F) Immunofluorescence staining of CXCR3 (green) in granulosa cells.

FIGURE 5 | Change of collagen I in the ovaries of POI mice. (A) The distribution of blue-staining collagen in the ovaries from control mice and POI mice by Masson staining. (B) COL1A1 and COL1A2 protein levels in the ovaries from two groups, n=5. **P < 0.01 vs. control.
FIGURE 6 | Upregulation of COL1A1 and COL1A2 by CXCL10 in ovarian theca–stroma cells. (A) The morphology of ovarian theca–stroma cells under a microscope. (B) Immunofluorescence staining of vimentin (red) and CXCR3 (green) in ovarian theca–stroma cells. (C–F) Ovarian theca–stroma cells were treated with vehicle control (0) and CXCL10 (1, 10, and 100 ng/ml) for 24 h. (C) COL1A1 mRNA level, (D) COL1A1 protein level, (E) COL1A2 mRNA level, and (F) COL1A2 protein level were measured. *P < 0.05, **P < 0.01 vs. vehicle control (0).

FIGURE 7 | Involvement of JNK and c-Jun in the regulation of collagen I by CXCL10 in ovarian theca–stroma cells. (A) Time course effects of CXCL10 (10 ng/ml) on the phosphorylation of JNK in ovarian theca–stroma cells. (B, C) Effects of CXCL10 (10 ng/ml, 24 h) on the protein levels of COL1A1 and COL1A2 in the presence or absence of inhibitors for JNK (SP600125, 10 μM). (D) Time course effects of CXCL10 (10 ng/ml) on the phosphorylation of c-Jun in ovarian theca–stroma cells. (E) Effects of CXCL10 (10 ng/ml, 15 min) on the phosphorylation of c-Jun in the presence or absence of inhibitors for JNK (SP600125, 10 μM). (F, G) Effect of CXCL10 (10 ng/ml, 24 h) on COL1A1 and COL1A2 protein levels in the presence or absence of siRNA-mediated knockdown of c-Jun. n = 3. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. CXCL10.
models, but to date, a no less severe bPOI animal model has been reported (35). Further in-vivo studies are needed to investigate the effect of CXCL10 on ovarian fibrosis by recombinant CXCL10 protein. Moreover, it is important to assess the therapeutic potential of CXCL10 neutralization antibody or CXCR3 silencing in both bPOI and POI mouse models.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Institutional Animal Care and Use Committee at Renji Hospital, School of Medicine, Shanghai Jiao Tong University.

**REFERENCES**

1. Vander Borght M, Wyns C. Fertility and infertility: Definition and Epidemiology. Clin Biochem (2018) 62:2–10. doi: 10.1016/j.clinbiochem.2018.03.012

2. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber I, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: Management of Women With Premature Ovarianinsufficiency. Hum Reprod (2016) 31:926–37. doi: 10.1093/humrep/dew027

3. Deng Y, Wang X, Hao Y, Zhang X, Zhao S, Ma J, et al. MicroRNA-379-5p is Associate With Biochemical Premature Ovarianinsufficiency Through PARP1 and XRCC6. Cell Death Dis (2018) 9:106. doi: 10.1038/s41419-017-0163-8

4. Cui L, Bao H, Liu Z, Man X, Liu H, Hou Y, et al. HMUSCs Regulate the Differentiation of Ovarian Stromal Cells via TGF-Beta1/Smad3 Signaling Pathway to Inhibit Ovarian Fibrosis to Repair Ovarian Function in POI Rats. Stem Cell Res Ther (2020) 7:11386. doi: 10.1186/s13287-020-01904-3

5. Berkholz CB, Lai BE, Woodruff TK, Shea LD. Distribution of Extracellular Matrix Proteins Type I collagen, type IV collagen, fibronectin, and Laminin in Mouse Folliculogenesis. Histochem Cell Biol (2006) 126:583–92. doi: 10.1007/s00418-006-0194-1

6. Briley SM, Jasti S, McCracken JM, Hornick JE, Fegley B, Pritchard MT, et al. Reproductive age-Associated Fibrosis in the Stroma of the Mammalian Ovary. Reproduction (2016) 152:245–60. doi: 10.1530/REP-16-0129

7. Zhou F, Shi LB, Zhang SY. Ovarian Fibrosis: A Phenomenon of Concern. Chin Med J (Engl) (2017) 130:365–71. doi: 10.4103/0366-6999.198931

8. Wang D, Weng Y, Zhang Y, Wang R, Wang T, Zhou J, et al. Exposure to Hyperandrogen Drives Ovarian Dysfunction and Fibrosis by Activating the NLRP3 Inflammasome in Mice. Sci Total Environ (2020) 745:141049. doi: 10.1016/j.scitotenv.2020.141049

9. Candelaria NR, Padmanabhan A, Stossi F, Ljungberg MC, Shelly KE, Pew BK, et al. VCAM1 Is Induced in Ovarian Theca and Stromal Cells in a Mouse Model of Androgen Excess. Endocrinology (2019) 160:1377–93. doi: 10.1210/en.2018-00731

10. Schmidt J, Weijdegård B, Mikkelsen AL, Lindenberg S, Nilsson L, Brännström M. Differential Expression of Inflammation-Related Genes in the Ovarian Stromaand Granulosa Cells of PCOS Women. Mol Hum Reprod (2014) 20:49–58. doi: 10.1093/molehr/gat051

11. Erlebacher A, Zhang D, Parlow AF, Glimcher LH. Ovarian insufficiency and Early Pregnancy Loss Induced by Activation of the Innate Immune System. J Clin Invest (2004) 114:34–48. doi: 10.1172/JCI20645

12. Yang Z, Tang Z, Cao X, Xie Q, Hu C, Zhong Z, et al. Controlling Chronic Low-Grade Inflammation to Improve Follicle Development and Survival. Am J Reprod Immunol (2020) 84:e13265. doi: 10.11151/ajr13265

13. Huang Y, Hu C, Ye H, Luo R, Fu X, Li X, et al. InflamM-Aging: A New Mechanism Affecting Premature Ovarian Insufficiency. J Immunol Res (2019) 2019:8069898. doi: 10.1155/2019/8069898

14. Gao J, Jiao X, Dang Y, Li J, Li G, Han T, et al. Identification of Patients With Primary Ovarian Insufficiency Caused by Autoimmunity. Reprod BioMed Online (2017) 35:475–9. doi: 10.1016/j.rbmo.2017.06.010

15. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF. Bonfá EAAutoimmune Primary Ovarian Insufficiency. Autoimmun Rev (2014) 13:427–30. doi: 10.1016/j.autrev.2014.01.003

16. Jiao X, Zhang X, Li N, Zhang D, Zhao S, Dang Y, et al. T(reg) deficiency-Mediated T(H) 1 Response Causes Human Premature Ovarian Insufficiency Through Apoptosis and Steroidogenesis Dysfunction of Granulosa Cells. Clin Transl Med (2021) 11:e448. doi: 10.1002/ctm2.448

17. Karin N. CXCR3 Ligands in Cancer and Autoimmunity, Chemotraction of Effector TCells, and Beyond. Front Immunol (2020) 11:976. doi: 10.3389/fimmu.2020.00976

18. Lee EY, Lee ZH, Song YW. CXCL10 and Autoimmune Diseases. Autoimmun Rev (2009) 8:379–83. doi: 10.1016/j.autrev.2008.12.002

19. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germine stem cells and Follicular Renewal in the Postnatal Mammalian Ovary. Nature (2004) 428:145–50. doi: 10.1038/nature02316

20. Zhang H, Luo Q, Lu X, Yin N, Zhou D, Zhang L, et al. Effects of hPMSCs on Granulosa Cell Apoptosis and AMH Expression and Their Role in the Restoration of Ovary Function in Premature Ovarian Failure Mice. Stem Cell Res Ther (2018) 9:20. doi: 10.1186/s13287-017-0745-5

21. Qi J, Li J, Wang Y, Wang W, Zhu Q, He Y, et al. Novel Role of CXCL14 in Autoimmune Primary Ovarian Insufficiency. Cell Res Ther (2018) 9:20. doi: 10.1186/s13287-017-0745-5

22. Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and Autoimmunity—an Update Appraisal. J Assist Reprod Genet (2019) 36:2207–15. doi: 10.1007/s10815-019-01572-0

**AUTHOR CONTRIBUTIONS**

YS conceived and designed the experiments. CW performed the experiments, analyzed the data, and wrote the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Key R&D Program of China (2019YFA0802604); National Natural Science Foundation of China (Nos. 82130046, 81771648, 81801408); Shanghai Leading Talent Program, Innovative Research Team of High-Level Local Universities in Shanghai (No. SSMU-ZLCX20180401); Clinical Research Plan of SHDC (SHDC2020CR1046B); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161413); and Shanghai Commission of Science and Technology (No. 17DZ2271100).
23. Zhou XY, Zhang J, Li Y, Chen YX, Wu XM, Li X, et al. Advanced Oxidation Protein Products Induce G1/G0-Phase Arrest in Ovarian Granulosa Cells via the ROS-JNK/p38 MAPK-P21 Pathway in Premature Ovarian Insufficiency. Oxid Med Cell Longev (2021) 2021:6634718. doi: 10.1155/2021/6634718

24. Liu P, Zhang X, Hu J, Cui L, Zhao S, Jiao X, et al. Dysregulated cytokine profile Associated With Biochemical Premature Ovarian Insufficiency. Am J Reprod Immunol (2020) 84:e13292. doi: 10.1111/aji.13292

25. Berkholz CB, Lai BE, Woodruff TK, Shea LD. Distribution of Extracellular Matrix Proteins Type I collagen, type IV collagen, Fibronectin, and Laminin in Mouse Folliculogenesis. Histochem Cell Biol (2006) 126:583–92. doi: 10.1007/s00418-006-0194-1

26. Hintermann E, Bayer M, Pfeilschifter JM, Luster AD, Christen U. CXCL10 promotes Liver Fibrosis by Prevention of NK cell Mediated Hepatic Stellate Cell Inactivation. J Autoimmun (2010) 35:424–35. doi: 10.1016/j.jaut.2010.09.003

27. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, et al. Serum Chemokine CXC Ligand 10 (CXCL10) Predicts Fibrosis Progression After Liver Transplantation for Hepatitis C Infection. Hepatology (2011) 53:596–603. doi: 10.1002/hep.24098

28. Jiang D, Liang J, Campanella GS, Guo R, Yu S, Xie T, et al. Inhibition of Pulmonary Fibrosis in Mice by CXCL10 requires Glycosaminoglycan Binding and Syndecan-4. J Clin Invest (2010) 120:2049–57. doi: 10.1172/JCI38644

29. Gui X, Qiu X, Tian Y, Xie M, Li H, Gao Y, et al. Prognostic Value of IFN-Gamma, Scd163, CCL2 and CXCL10 involved in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Int Immunopharmacol (2019) 70:208–15. doi: 10.1016/j.intimp.2019.02.039

30. Zhang Y, Thai K, Kepecs DM, Winer D, Gilbert RE. Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. Am J Pathol (2018) 188:2763–73. doi: 10.1016/j.ajpath.2018.08.017

31. Mikolajczyk TP, Szczepaniak P, Vidler F, Maffia P, Graham GJ, Guzik TJ. Role of Inflammatory Chemokines in Hypertension. Pharmacol Ther (2021) 223:107799. doi: 10.1016/j.pharmthera.2020.107799

32. Grzybek K, Ma FY, Nikolic-Paterson DJ. The JNK Signaling Pathway in Renal Fibrosis. Front Physiol (2017) 8:829. doi: 10.3389/fphys.2017.00829

33. Kook SH, Hwang JM, Park JS, Kim EM, Heo JS, Jeon YM, et al. Mechanical Force Induces Type I collagen expression in Human Periodontal Ligament Fibroblasts Through Activation of ERK/JNK and AP-1. J Cell Biochem (2009) 106:1060–7. doi: 10.1002/jcb.22085

34. Lin CH, Yu MC, Tung WH, Chen TT, Yu CC, Weng CM, et al. Connective tissue growth factor induces Collagen I Expression in Human Lung Fibroblasts Through the Rac1/MLK3/JNK/AP-1 Pathway. Biochim Biophys Acta (2013) 1833:2823–33. doi: 10.1016/j.bbamcr.2013.07.016

35. Buigues A, Marchante M, Herraiz S, Pellicer A. Diminished Ovarian Reserve Chemotherapy-Induced Mouse Model: A Tool for the Preclinical Assessment of New Therapies for Ovarian Damage. Reprod Sci (2020) 27:1609–19. doi: 10.1007/s43032-020-00191-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.